Pfizer asks US to allow COVID shots for kids ages 5 to 11
By LAURAN NEERGAARD and JENNIFER McDERMOTT
Pfizer asked the U.S. government Thursday to allow use of its COVID-19 vaccine in children ages 5 to 11 in what would be a major expansion that could combat an alarming rise in serious infections in youngsters and help schools stay open.
If regulators give the go-ahead, reduced-dose kids’ shots could begin within a matter of weeks for the roughly 28 million children in that age group.
Many parents and pediatricians are clamoring for protection for youngsters under 12, the current age cutoff for COVID-19 vaccinations in the U.S.
The Food and Drug Administration will have to decide whether the shots are safe and effective in elementary school-age children. An independent expert panel will publicly debate the evidence on Oct. 26.
Pfizer and its German partner BioNTech said their research shows the younger kids should get one-third of the dose now given to everyone else. After their second dose, the 5- to 11-year-olds developed virus-fighting antibody levels just as strong as those that teens and young adults get from regular-strength shots.
While kids are at lower risk of severe illness or death than older people, COVID-19 does sometimes kill children — at least 520 so far in the U.S., according to the American Academy of Pediatrics. And cases in youngsters have skyrocketed as the extra-contagious delta variant has swept through the country.